Wegovy with a BMI Under 30: Who Qualifies and What the Rules Are

Step 1: Understand what the UK licence actually permits

Wegovy (semaglutide 2.4mg injection, made by Novo Nordisk) received its UK marketing authorisation for weight management in adults with a BMI of 30 or above, or a BMI between 27 and 29.9 where at least one weight-related comorbidity is present. The conditions that can satisfy that second criterion include type 2 diabetes, hypertension, dyslipidaemia and obstructive sleep apnoea, among others. You can read the full eligibility detail on the BMI criteria for Wegovy page.

Below BMI 27, Wegovy has no licensed weight-management indication in the UK. That is not a policy decision made by any individual pharmacy or clinic, it reflects what the medicine was tested and authorised for, as set out in its Summary of Product Characteristics published on the electronic Medicines Compendium.

Some people arrive at this question because they have lost weight since starting treatment and their BMI has dropped. That is a separate clinical situation and one your prescriber should review directly, it does not automatically mean treatment stops, but continuing would be an off-licence decision requiring a proper clinical rationale.

It is worth being honest about why this matters: the licensing framework exists because semaglutide carries real pharmacological effects and a known side-effect profile. Using it at weights where the benefit-to-risk balance has not been formally established is not something any responsible UK prescriber will do without strong clinical grounds.

Step 2: Check whether BMI 27–29.9 applies to your situation

If your BMI sits in the 27–29.9 range, the route to Wegovy is still open, provided your health history includes at least one qualifying condition. This is where the assessment becomes genuinely clinical rather than numerical.

High blood pressure is one of the most common qualifying conditions at this BMI level; so is a raised cholesterol profile or pre-diabetes. If you are not sure whether your existing health conditions meet the threshold, that is exactly the kind of question a prescriber can work through with you at consultation. You can explore what counts as a weight-related condition on the BMI 25 and Wegovy page, which covers the lower end of this range in more detail.

For adults of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance reduces the standard BMI thresholds by 2.5 kg/m². In practice that means the 27 threshold becomes 24.5, and the 30 threshold becomes 27.5. The BMI needed to take Wegovy page covers these adjustments with the relevant NHS source.

One thing our prescribers are asked fairly often: can a GP prescribe Wegovy off-licence if BMI is under 27? Technically a doctor may prescribe off-licence, but it must be clinically justified, documented and explained to the patient, and the NHS does not fund it in that context. Most UK clinicians will not do so for weight management alone at a BMI below 27.

Step 3: Work out your realistic options and next steps

If you fall below the BMI threshold for Wegovy, there are a few honest directions worth considering. First, check your BMI accurately, the NHS BMI calculator is a reliable starting point, and BMI readings can shift meaningfully depending on when and how they are taken. If you are close to 27 and have a relevant health condition, a consultation is still worth pursuing.

Second, consider whether another licensed treatment fits better. Mounjaro (tirzepatide) carries the same BMI thresholds (≥30, or ≥27 with a comorbidity) so it does not open up access for those below 27 either. The Wegovy at BMI 28 page addresses the specific scenario of sitting just inside the 27–29.9 bracket. If you want a broader comparison of the treatment options available in the UK, the weight-loss treatment overview sets these out clearly.

Third, if your BMI is genuinely below 27 and none of the qualifying conditions apply, the honest answer is that Wegovy is not the right path right now. Lifestyle support, dietitian input and a conversation with your GP about underlying metabolic health are sensible starting points. That is not the answer most people searching this query want to read, we know that. But it is the correct one, and it is better you hear it plainly than discover it after a wasted consultation.

For a full overview of how semaglutide works and what to expect from treatment, the Wegovy treatment page covers the mechanism, the titration schedule and the evidence behind it. If you have questions about cost before committing to a consultation, the Wegovy price comparison page explains what the private market looks like and what a legitimate price includes.

What the NHS says, and how a private route differs

On the NHS, Wegovy is available only through specialist weight management services under NICE technology appraisal TA875, which sets stricter criteria than the licence alone, including a BMI of 35 or above in most cases, at least one comorbidity and multidisciplinary support. The NICE guidance on semaglutide (TA875) sets this out in full. For the vast majority of people with a BMI under 30, NHS access is not a realistic near-term option.

Private prescribing through a registered online pharmacy follows the licensed criteria directly: BMI ≥30, or ≥27 with a qualifying condition. That is the floor. Our prescribers at about us work to exactly those standards, a named clinician reads every consultation, considers your health history and decides on that basis. No consultation is a rubber stamp.

If you are at or above the threshold and ready to find out whether Wegovy is clinically appropriate for you, speaking to our prescribers is the right next step.

Speak to our prescribers, start your free consultation.